Does Guideline Adherence for Empiric Antibiotic Therapy Reduce Mortality in Community-acquired Pneumonia?

2005 ◽  
Vol 172 (6) ◽  
pp. 655-656 ◽  
Author(s):  
Drahomir Aujesky ◽  
Michael J. Fine
2018 ◽  
Vol 24 (6) ◽  
pp. 658.e1-658.e6 ◽  
Author(s):  
X.M. Nie ◽  
Y.S. Li ◽  
Z.W. Yang ◽  
H. Wang ◽  
S.Y. Jin ◽  
...  

2018 ◽  
Vol 5 (suppl_1) ◽  
pp. S268-S268
Author(s):  
Reed Siemieniuk ◽  
Yung Lee ◽  
Isaac Bogoch ◽  
Romina Brignardello-Petersen ◽  
Yutong Fei ◽  
...  

Abstract Background Community-acquired pneumonia (CAP) is one of the top causes of life-years lost globally. The optimal empiric antibiotic therapy regimen is uncertain. Randomized controlled trials (RCTs) provide useful information about relative antibiotic effectiveness. Methods We systematically searched Medline, EMBASE, and CENTRAL for RCTs comparing at least two empiric antibiotic regimens in patients with CAP, to March 17, 2017. We performed a systematic review and network meta-analysis and network meta-regression using a Bayesian framework. We used GRADE to assess certainty in the effect estimates. Results From 18,056 citations, we included 303 RCTs. Most studies (69.9%) were not blinded. All networks had low global heterogeneity (I2 0%). There were 26,423 participants included in the analysis of mortality and 30,559 for treatment failure. Seven hundred and twenty-six (2.9%) participants died. Patients randomized to third generation cephalosporins alone had higher mortality than those randomized to early generation fluoroquinolones (risk ratio [RR] 2.08, 95% credible interval 1.17–3.90), later generation fluoroquinolones (RR 2.32, 1.44–4.26), and cephalosporin-fluoroquinolone combinations (RR 3.21, 0.99–12.49). Participants who were randomized to a cephalosporin plus macrolide were less likely to die than those who received a third generation cephalosporin alone (RR 0.47, 0.21–0.99). The evidence was similar for treatment failure. Β-lactam plus β-lactamase inhibitors (e.g., piperacillin–tazobactam), early generation cephalosporins, and daptomycin appeared to confer a higher risk of mortality and/or treatment failure than most other antibiotic regimens including third-generation cephalosporins alone. For key comparisons, the GRADE quality of evidence was low or moderate. Conclusion In patients with CAP, an antibiotic regimen that includes a fluoroquinolone (and possibly a macrolide) may reduce mortality by ~1–2% compared with β-lactams (with or without a β-lactamase inhibitor) and cephalosporins alone. High quality, blinded and pragmatic randomized evidence would be helpful to increase certainty in the evidence. Disclosures All authors: No reported disclosures.


2006 ◽  
Vol 119 (10) ◽  
pp. 865-871 ◽  
Author(s):  
Christopher R. Frei ◽  
Marcos I. Restrepo ◽  
Eric M. Mortensen ◽  
David S. Burgess

2016 ◽  
Vol 29 (4) ◽  
pp. 386-391 ◽  
Author(s):  
Beth L. Erwin ◽  
Jeffrey A. Kyle ◽  
Leland N. Allen

Purpose: The 2005 American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA) guidelines for hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and health care-associated pneumonia (HCAP) stress the importance of initiating prompt appropriate empiric antibiotic therapy. This study’s purpose was to determine the percentage of patients with HAP, VAP, and HCAP who received guideline-based empiric antibiotic therapy and to determine the average time to receipt of an appropriate empiric regimen. Methods: A retrospective chart review of adults with HAP, VAP, or HCAP was conducted at a community hospital in suburban Birmingham, Alabama. The hospital’s electronic medical record system utilized International Classification of Diseases, Ninth Revision ( ICD-9) codes to identify patients diagnosed with pneumonia. The percentage of patients who received guideline-based empiric antibiotic therapy was calculated. The mean time from suspected diagnosis of pneumonia to initial administration of the final antibiotic within the empiric regimen was calculated for patients who received guideline-based therapy. Results: Ninety-three patients met the inclusion criteria. The overall guideline adherence rate for empiric antibiotic therapy was 31.2%. The mean time to guideline-based therapy in hours:minutes was 7:47 for HAP and 28:16 for HCAP. For HAP and HCAP combined, the mean time to appropriate therapy was 21:55. Conclusion: Guideline adherence rates were lower and time to appropriate empiric therapy was greater for patients with HCAP compared to patients with HAP.


Sign in / Sign up

Export Citation Format

Share Document